Although c-MYC contributes to tamoxifen resistance, it improves cisplatin sensitivity in ER-positive breast cancer

Tamoxifen (TAM) resistance is a major challenge in the treatment of estrogen receptor-positive (ER(+)) breast cancer. To date, to the best of our knowledge, there are only a few studies available examining the response of patients with TAM-resistant breast cancer to chemotherapy, and the guidelines...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Int J Oncol
Auteurs principaux: Chen, Rui, Guo, Shipeng, Yang, Chengcheng, Sun, Lu, Zong, Beige, Li, Kang, Liu, Li, Tu, Gang, Liu, Manran, Liu, Shengchun
Format: Artigo
Langue:Inglês
Publié: D.A. Spandidos 2020
Sujets:
Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7050981/
https://ncbi.nlm.nih.gov/pubmed/32319562
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ijo.2020.4987
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires